Progyny, Inc.
PGNY scores 47.4 on the Conservative profile, blending a fundamental score (80% weight, emphasizing quality and stability (84% of fundamental weight)) with a machine-learning signal (20% weight) trained on 82 features across 30 years of data.
Minor adjustments (-0.5 points) applied. PGNY's rank of #688 primarily reflects its factor profile relative to the conservative weight vector.
These features are direct inputs to the machine learning model. The model was trained on these signals alongside 100 features (including 12 momentum/technical indicators) to produce the ML percentile score.
| Stock | Score | P/E | Rev Growth | Margin | Mkt Cap |
|---|---|---|---|---|---|
| PGNY | 47.4 | 31.9 | 7.2% | 4.5% | $1.8B |
| INCY | 89.9 | 15.8 | 21.2% | 25.0% | $19.6B |
| GMAB | 86.1 | 13.1 | 22.8% | 36.4% | $17.9B |
| CPRX | 83.7 | 13.7 | 23.5% | 37.6% | $3.0B |
| EXEL | 78.3 | 15.1 | 7.0% | 33.7% | $11.9B |
| ASND | 78.2 | 16.6 | 98.0% | -31.7% | $13.8B |
| VRTX | 78.2 | 32.1 | 8.9% | 32.9% | $121.8B |
| NBIX | 75.1 | 26.5 | 21.4% | 16.7% | $13.1B |
| RPRX | 75.0 | 25.1 | 5.1% | 32.4% | $19.3B |
| HOLX | 74.8 | 31.1 | 1.7% | 13.8% | $16.8B |
| AMGN | 74.2 | 26.0 | 10.0% | 21.0% | $204.8B |
| ARGX | 73.7 | 35.1 | 78.6% | 38.0% | $47.4B |
| REGN | 73.0 | 19.4 | 1.0% | 31.4% | $80.2B |
| ALKS | 72.9 | 16.5 | -6.4% | 23.9% | $5.0B |
| ISRG | 72.7 | 61.7 | 20.5% | 28.4% | $180.9B |
| KRYS | 71.5 | 41.4 | 473.0% | 30.7% | $7.9B |
| Sector Average | 36.4 | 41.9 | 161.5% | -3292.7% | â |
Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimbursement programs for employers. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
Stock is in a downtrend below the 200-day moving average. Price is below both the 50-day and 200-day SMAs, indicating sustained selling pressure.
| Metric | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|
| Revenue | $313M | $333M | $324M | $298M |
| Gross Profit | $73M | $79M | $76M | $63M |
| Operating Income | $22M | $24M | $24M | $16M |
| Net Income | $14M | $17M | $15M | $11M |
| EPS (Diluted) | $0.15 | $0.19 | $0.17 | $0.12 |
| Gross Margin | 23.2% | 23.7% | 23.4% | 21.3% |
| Operating Margin | 6.9% | 7.3% | 7.5% | 5.3% |
| Net Margin | 4.4% | 5.1% | 4.6% | 3.5% |
| Year | Low | High | Range | Status |
|---|---|---|---|---|
| 2021 | $38.61 | $68.32 | 55.6% | Wide |
| 2022 | $25.67 | $53.10 | 69.6% | Wide |
| 2023 | $28.03 | $44.95 | 46.4% | Wide |
| 2024 | $13.39 | $42.08 | 103.4% | Wide |
| 2025 | $17.01 | $27.76 | 48% | Wide |
Growth estimates have been dampened based on technical and fundamental signals. This is a post-hoc adjustment to prevent overly optimistic projections for stocks showing declining momentum or deteriorating fundamentals.
Scores are generated by a multi-stage ML pipeline combining fundamental analysis, ensemble predictions, and structural risk signals. All data is for research purposes only and does not constitute financial advice. Past performance does not guarantee future results.